'Quantamental' Japan Specialist, LightStream Research

Campbell Gunn

'Quantamental' Japan Specialist

ja research

ja research is an independent research platform focused exclusively on Japanese equities. Leveraging data and graphic analysis provided by Japan Analytics, we provide insights on small and medium-sized companies that have been ignored by the sell-side as well as challenging conventional wisdom on larger companies. We also offer analyst and corporate access, the latter with translation if required. 

Thematic (Sector/Industry)

A recent Bloomberg article (<a href="https://www.bloomberg.com/news/articles/2018-07-24/the-other-earnings-season-small-cap-zombies-go-nowhere-but-up" target="_blank">https://www.bloomberg.com/news/articles/2018-07-24/the-other-earnings-season-small-cap-zombies-go-nowhere-but-up</a>) pointed out that, in the US, one-third of Russell 2000 companies are money-losing, but so far this year have out-performed profitable companies by 5.3% this year. The article included a chart from The Leuthold Group showing the loss-making percentage for small caps since 1995.<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/059/020/original/File%202018-07-26%2012%2054%2030.jpeg?1532605813" class="editor-image img-responsive" data-smartkarma-image-id="59020"></figure><blockquote>“The past nine years’ extremely loose monetary policy has kept alive corporate…</blockquote>

A recent Bloomberg article (https://www.bloomberg.com/news/articles/2018-07-24/the-other-earnings-season-small-cap-zombies-go-nowhere-but-up) pointed out that, in the US, one-third of Russell 2000 companies are money-losing, but so far this year have out-performed profitable companies by 5.3% this year. The article included a chart from The Leuthold Group showing the loss-making percentage for small caps since 1995.“The past nine years’ extremely loose monetary policy has kept alive corporate…

Japan: Fewer Zombies than the Russell 2000

Japan TMT Analyst

Pelham Smithers

Market Intel on Asian Tech with a Japan focus

Pelham Smithers Associates

Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods. 

Research is provided by the following:
Pelham Smithers: Macro, consumer electronics, telecoms & pharma
Joel Scheiman: Electronics materials / components
Julie Boote: Autos
Will Nestuk: Capital goods, machinery & transportation equipment parts
Thao Nguyen: eCommerce, internet content, marketing & advertising

Equity Bottom-Up

On the surface, <a href="https://www.smartkarma.com/entities/13514" target="_blank" data-smartkarma-citation="entities:13514:1">Peptidream's (4587 JP)</a> deal with <a href="https://www.smartkarma.com/entities/1132" target="_blank" data-smartkarma-citation="entities:1132:1">Johnson &amp; Johnson's (JNJ US)</a> Janssen unit looks no different from the deals they have cut with other firms, with the exception of the total milestone payments. Normally, this is undisclosed, but in this instance, it has been announced – it is US$1.15bil – possibly because it is too large a number to be kept from investors, which is why the shares soared on Monday.  The deal sees J&amp;J access Peptidream's peptide drug conjugate capabilities as well…

On the surface, Peptidream's (4587 JP) deal with Johnson &amp; Johnson's (JNJ US) Janssen unit looks no different from the deals they have cut with other firms, with the exception of the total milestone payments. Normally, this is undisclosed, but in this instance, it has been announced – it is US$1.15bil – possibly because it is too large a number to be kept from investors, which is why the shares soared on Monday.  The deal sees J&amp;J access Peptidream's peptide drug conjugate capabilities as well…

PeptiDream: J&J Latest Drug Major to Tie Up

Japan

CellSeed Inc. develops Cell-sheet regenerative medicine. The company cultures cells and builds cell-sheets to regenerate lost or functionally imparied tissues and organs. CellSeed Inc. also supports regenerative medicine industry by providing leading technology and solutions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cellseed Inc (7776 JP)

Japan: Fewer Zombies than the Russell 2000

A recent Bloomberg article (https://www.bloomberg.com/news/articles/2018-07-24/the-other-earnings-season-small-cap-zombies-go-nowhere-but-up)...

Campbell Gunn

PeptiDream: J&J Latest Drug Major to Tie Up

On the surface, Peptidream's (4587 JP) deal with Johnson & Johnson's (JNJ US) Janssen unit looks no different from the deals they have cut with...

Pelham Smithers Associates

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)